TetraLogic Pharmaceuticals Corp. (Nasdaq: TLOG) temporarily halted enrollment in a chronic hepatitis B trial sending the stock price plummeting $1.38 to close at $2.40.
TetraLogic halts study enrollment
May 06, 2015 at 17:11 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.